NR4A1 and posterior cortical atrophy: However, these tools are not necessarily universal, given that they are restricted to subsets of patients based on criteria such as hormone receptor, pathological types and nodal status (39, 40). It is urgent to explore better biomarkers or predictive tools for PCa.